Use of inhibitors of scinderin and/or ephrin-A1 for treating...

Details Use of inhibitors of scinderin and/or ephrin-A1 for treating... Use of inhibitors of scinderin and/or ephrin-A1 for treating...

2006-12-28

2011-11-15

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C435S455000, C424S093210

Reexamination Certificate

active

08058252

ABSTRACT:
The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.

REFERENCES:
patent: 6184352 (2001-02-01), Nakamura et al.
patent: 2003/0091569 (2003-05-01), Gerritsen et al.
patent: 2004/0029275 (2004-02-01), Brown et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
Carter et al. (2002) Nature Cell Biology 4:565-73.
Trifaro et al. (2000) Neurochemical Research, vol. 25, No. 1, pp. 133-144.
Bass (2001) Nature 411:428-9.
Afroze et al. (2003) Am J Physiol Cell Physiol 285: C88-C95, 2003.
Lueck et al. (2000) Biochemistry 39: 5274-5279.
Khong et al (Nature Immunol. 3(11): 999-1005).
Garcia-Lora (J. Cell. Physiol. 195 :346-345, 2003).
Otten et al (Leukemia, 2004, vol. 18, pp. 1401-1405).
Macrae et al. “A conditional feedback loop regulates Ras activity through EphA2” Cancer Cell, 8, pp. 111-118 (2005).
Chen et al. “Inhibition of retinal neovascularization by soluble EphA2 receptor” Experimental Eye Research, 82, pp. 664-673 (2005).
Ogawa et al. “The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization” Oncogene, 19, pp. 6043-6052 (2000).
Lejen et al. “An antisense oligodeoxynucleotide targeted to chromaffin cell scinderin gene decreased scinderin levels and inhibited depolarization-induced cortical F-actin disassembly and exocytosis” J. Neurochem., 76, pp. 768-777 (2001).
Abouzahr et al. “Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure” PNAS, 103(5), pp. 1428-1433 (2006).
Brantley-Sieders et al. “Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice” Cancer Research, 66(21), pp. 10315-10324 (2006).

Affiliated with

Also associated with

Rating

Use of inhibitors of scinderin and/or ephrin-A1 for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of inhibitors of scinderin and/or ephrin-A1 for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of scinderin and/or ephrin-A1 for treating... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4267431